- Product Details
Keywords
- Upadacitinib hemihydrate
- 2050057-56-0
- 99%
Quick Details
- ProName: Upadacitinib hemihydrate
- CasNo: 2050057-56-0
- Molecular Formula: C17H21F3N6O2
- Appearance: color
- Application: INTERMEDITD
- DeliveryTime: In Stock
- PackAge: According to your
- Port: Shang Hai
- ProductionCapacity: 1 Kilogram/Day
- Purity: 99%
- Storage: storage temp
- Transportation: Air,Sea,courier
- LimitNum: 1 Kilogram
Superiority
Upadacitinib hemihydrate
1-Pyrrolidinecarboxamide,3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-,hydrate(2:1),(3S,4R)-;UpadacitinibhemihydraChemicalbookte;UpadacitinibHydrate;Cinchonanium,1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'-[[3-(trifluoromethyl)phenyllmethyl},bromide(1:2),(8a,9R)-"
InChIKeyVJSRYIXHEWRBKD-NFGOAHBONA-NSMILESC([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r|
2050057-56-0
C17H21F3N6O2
398.39
Details
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD)1. It is used in the treatment of rheumatoid arthritis to slow down disease progression1. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints1. Upadacitinib works by blocking the action of enzymes called Janus kinases, which are involved in setting up processes that lead to inflammation
Upadacitinib hemihydrate
1-Pyrrolidinecarboxamide,3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-,hydrate(2:1),(3S,4R)-;UpadacitinibhemihydraChemicalbookte;UpadacitinibHydrate;Cinchonanium,1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'-[[3-(trifluoromethyl)phenyllmethyl},bromide(1:2),(8a,9R)-"
InChIKeyVJSRYIXHEWRBKD-NFGOAHBONA-NSMILESC([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r|
2050057-56-0
C17H21F3N6O2
398.39